Anebulo Pharmaceuticals Net Income
| ANEB Stock | USD 0.50 0.32 39.02% |
As of the 9th of February, Anebulo Pharmaceuticals shows the mean deviation of 4.87, and Risk Adjusted Performance of (0.19). Anebulo Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Anebulo Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Anebulo Pharmaceuticals' valuation are provided below:We have found ninety-seven available fundamental signals for Anebulo Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Anebulo Pharmaceuticals prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -10.6 M | -10 M | |
| Net Loss | -9.8 M | -10.2 M | |
| Net Loss | -9.8 M | -10.2 M | |
| Net Loss | (0.23) | (0.24) |
Anebulo | Net Income | Build AI portfolio with Anebulo Stock |
Analyzing Anebulo Pharmaceuticals's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Anebulo Pharmaceuticals's current valuation and future prospects.
Latest Anebulo Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Anebulo Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Anebulo Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Anebulo Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Anebulo Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anebulo Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (8.48 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Anebulo Net Income Regression Statistics
| Arithmetic Mean | (5,132,172) | |
| Coefficient Of Variation | (153.38) | |
| Mean Deviation | 5,832,394 | |
| Median | (174,637) | |
| Standard Deviation | 7,871,861 | |
| Sample Variance | 62T | |
| Range | 30.1M | |
| R-Value | (0.57) | |
| Mean Square Error | 44.4T | |
| R-Squared | 0.33 | |
| Significance | 0.02 | |
| Slope | (892,117) | |
| Total Sum of Squares | 991.5T |
Anebulo Net Income History
Other Fundumenentals of Anebulo Pharmaceuticals
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Anebulo Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Anebulo Pharmaceuticals is extremely important. It helps to project a fair market value of Anebulo Stock properly, considering its historical fundamentals such as Net Income. Since Anebulo Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Anebulo Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Anebulo Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Anebulo Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Anebulo Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Anebulo Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Anebulo Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Anebulo Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Anebulo Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Anebulo Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Anebulo Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Anebulo Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Anebulo Pharmaceuticals.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Anebulo Pharmaceuticals on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Anebulo Pharmaceuticals or generate 0.0% return on investment in Anebulo Pharmaceuticals over 90 days. Anebulo Pharmaceuticals is related to or competes with Tiziana Life, Immix Biopharma, Whitehawk Therapeutics, Zentalis Pharmaceuticals, Coya Therapeutics, Pliant Therapeutics, and Clene. Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatme... More
Anebulo Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Anebulo Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Anebulo Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.26) | |||
| Maximum Drawdown | 36.64 | |||
| Value At Risk | (15.74) | |||
| Potential Upside | 5.06 |
Anebulo Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Anebulo Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Anebulo Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Anebulo Pharmaceuticals historical prices to predict the future Anebulo Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.19) | |||
| Jensen Alpha | (1.91) | |||
| Total Risk Alpha | (2.86) | |||
| Treynor Ratio | 1.11 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Anebulo Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Anebulo Pharmaceuticals February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.19) | |||
| Market Risk Adjusted Performance | 1.12 | |||
| Mean Deviation | 4.87 | |||
| Coefficient Of Variation | (398.06) | |||
| Standard Deviation | 8.14 | |||
| Variance | 66.33 | |||
| Information Ratio | (0.26) | |||
| Jensen Alpha | (1.91) | |||
| Total Risk Alpha | (2.86) | |||
| Treynor Ratio | 1.11 | |||
| Maximum Drawdown | 36.64 | |||
| Value At Risk | (15.74) | |||
| Potential Upside | 5.06 | |||
| Skewness | (2.10) | |||
| Kurtosis | 8.38 |
Anebulo Pharmaceuticals Backtested Returns
Anebulo Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.25, which signifies that the company had a -0.25 % return per unit of standard deviation over the last 3 months. Anebulo Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Anebulo Pharmaceuticals' mean deviation of 4.87, and Risk Adjusted Performance of (0.19) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -1.85, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Anebulo Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Anebulo Pharmaceuticals is expected to outperform it. At this point, Anebulo Pharmaceuticals has a negative expected return of -2.08%. Please make sure to confirm Anebulo Pharmaceuticals' coefficient of variation, treynor ratio, skewness, as well as the relationship between the jensen alpha and value at risk , to decide if Anebulo Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.82 |
Very good predictability
Anebulo Pharmaceuticals has very good predictability. Overlapping area represents the amount of predictability between Anebulo Pharmaceuticals time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Anebulo Pharmaceuticals price movement. The serial correlation of 0.82 indicates that around 82.0% of current Anebulo Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.82 | |
| Spearman Rank Test | 0.46 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Anebulo Pharmaceuticals reported net income of (8.48 Million). This is 102.49% lower than that of the Biotechnology sector and 112.11% lower than that of the Health Care industry. The net income for all United States stocks is 101.49% higher than that of the company.
Anebulo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Anebulo Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Anebulo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Anebulo Pharmaceuticals by comparing valuation metrics of similar companies.Anebulo Pharmaceuticals is currently under evaluation in net income category among its peers.
Anebulo Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Anebulo Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Anebulo Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Anebulo Pharmaceuticals' value.| Shares | Blackrock Inc | 2025-06-30 | 17.2 K | Goldman Sachs Group Inc | 2025-06-30 | 11.6 K | Bank Of America Corp | 2025-06-30 | 3.5 K | Tower Research Capital Llc | 2025-06-30 | 3.3 K | Pnc Financial Services Group Inc | 2025-06-30 | 1.5 K | Ubs Group Ag | 2025-06-30 | 92.0 | Ameritas Advisory Services, Llc | 2025-06-30 | 10.0 | King Luther Capital Management Corp | 2025-03-31 | 0.0 | Jpmorgan Chase & Co | 2025-06-30 | 0.0 | 22nw, Lp | 2025-06-30 | 15.5 M | Nantahala Capital Management, Llc | 2025-06-30 | 3 M |
Anebulo Fundamentals
| Return On Equity | -1.45 | ||||
| Return On Asset | -0.86 | ||||
| Current Valuation | 10.13 M | ||||
| Shares Outstanding | 40.78 M | ||||
| Shares Owned By Insiders | 40.53 % | ||||
| Shares Owned By Institutions | 54.40 % | ||||
| Number Of Shares Shorted | 58.05 K | ||||
| Price To Book | 2.10 X | ||||
| EBITDA | (8.1 M) | ||||
| Net Income | (8.48 M) | ||||
| Cash And Equivalents | 14.55 M | ||||
| Cash Per Share | 0.62 X | ||||
| Total Debt | 487.69 K | ||||
| Current Ratio | 30.40 X | ||||
| Book Value Per Share | 0.24 X | ||||
| Cash Flow From Operations | (6.35 M) | ||||
| Short Ratio | 0.45 X | ||||
| Earnings Per Share | (0.22) X | ||||
| Target Price | 3.0 | ||||
| Beta | -0.81 | ||||
| Market Capitalization | 20.41 M | ||||
| Total Asset | 12.15 M | ||||
| Retained Earnings | (73.89 M) | ||||
| Working Capital | 11.47 M | ||||
| Net Asset | 12.15 M |
About Anebulo Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Anebulo Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anebulo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anebulo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Anebulo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anebulo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anebulo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anebulo Pharmaceuticals Stock:Check out For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Anebulo Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Anebulo Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Anebulo Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Anebulo Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Anebulo Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Anebulo Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Anebulo Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.